Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the receptor activator of NF kappa B ligand. OPG has been shown to be an important inhibitor of osteoclast differentiation and activation in rodent models. Estrogen is known to suppress bone resorption, and the action of estrogen on bone may be mediated by OPG. The relationship between endogenous estrogen and circulating OPG levels and bone status in human populations is unclear. Thus, the aim of this study was to investigate the relationship between biochemical markers of bone turnover and bone density and circulating OPG and endogenous estradiol levels in a population-based cohort of postmenopausal women. Subjects were 180 women ages 55-91 yr (mean age, 67 yr). Serum estradiol was measured using an auto-analyzer. Serum concentrations of OPG were determined by ELISA. Markers of bone formation and resorption were measured by standard methods. Bone mineral density at total body, total hip, femoral neck, and lumbar spine was measured by dual energy x-ray absorptiometry. There was a significant inverse relationship between estradiol and all bone turnover markers (r-values from -0.46 to -0.23; P < 0.05). Serum estradiol was positively related to absolute bone density at all sites and to change in bone density at the hip and femoral neck by univariate analysis (r-values from 0.15-0.29; P < 0.05). We observed a weak inverse association between OPG and serum-based bone turnover markers (r-values -0.18 and -0.16; P < 0.05). There was a significant positive relationship between OPG and bone mineral density at total body, total hip, and femoral neck (r-values from 0.17-0.2; P < 0.05) by univariate analysis, which was lost after adjustment for age and body mass index. There was a significant weak positive relationship between circulating OPG and serum estradiol (r = 0.18; P < 0.02). We observed no significant relationships between OPG and bone turnover markers measured in urine. We conclude that the variation in circulating endogenous estradiol levels is an important factor contributing to levels of bone turnover and bone density at the menopause. Our observations also suggest that circulating levels of OPG may reflect OPG activity in bone and are related to circulating endogenous levels of estradiol. We have previously reported high levels of variability in urine markers of bone resorption, and we suggest that this could account for the absence of a significant association between these markers and circulating OPG.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“Age appears to be a major factor influencing OPG levels in nearly all studies (372-377).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“Residual estrogen levels after the menopause correlate with bone density and fracture risk, yet the relationship of estrogen levels with serum OPG levels in postmenopausal women has been inconsistent across studies, with some supporting a weak relationship (375) and others no relationship (373, 379) or a negative correlation (381).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 1×
“The mean age of this group at the 5-yr visit was 67 yr (8).”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228 · cited 1×
“in transgenic mice designed to overexpress OPG, which develop osteopetrosis (8, 11).”
BackgroundIsolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · cited 1×
“The discovery of OPG in 1997 has enhanced our understanding of the way in which the processes of bone remodeling are regulated (8, 9 ). In vitro and animal studies have unambiguously revealed the role of OPG as a decoy receptor for receptor activator of NFB ligand (RANKL), neutralizing the effect of RANKL on the diffe…”
BackgroundSevere osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · cited 5×
“• Circulating Estradiol and OPG J Clin Endocrinol Metab, October 2002, 87(10):4470–4475 4471”
BackgroundInfluentialGarnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 2×
“osteoprotegerin (OPG) in human osteoblast-like cells (7).”
BackgroundRole of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Browner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506 · cited 3×
“(18), there was no relationship between OPG and bone density.”
BackgroundThe effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · cited 1×
“OPG has also been administered as a therapeutic agent, resulting in a dramatic reduction in bone turnover state, but little is known of its long-term effect on bone density (15).”
BackgroundEpidemiology of Vertebral Fractures
Schousboe, J. T. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.08.004 · Cited by 451
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · cited 4×
“culating levels of OPG than controls (13).”
BackgroundInfluentialHannon, R., Blumsohn, A., Naylor, K., & Eastell, R. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.7.1124 · Cited by 257 · cited 1×
“We believe that this may be due to the high level of biological variability encountered when making measurements of bone resorption in urine (17).”
BackgroundSelf-citationOsteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status1
Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., & Delmas, P. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7657 · Cited by 234 · cited 3×
“(19) observed a significant negative association between U-IFPD and OPG in men over the age of 40, but not in younger men.”
BackgroundOsteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Kostenuik, P., & Shalhoub, V. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397807 · Cited by 222
Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis—The Second Decade
Pacifici, R. (1998) · Endocrinology · doi:10.1210/endo.139.6.6087 · Cited by 194
The effect of 17β-estradiol on production of cytokines in cultures of peripheral blood
Rogers, A., & Eastell, R. (2001) · Bone · doi:10.1016/s8756-3282(01)00468-9 · Cited by 151
Self-citationChapurlat, R. D., Garnero, P., Bréart, G., Meunier, P. J., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.9.1835 · Cited by 98
Effects of Estrogen Therapy of Postmenopausal Women on Cytokines Measured in Peripheral Blood
Rogers, A., & Eastell, R. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.10.1577 · Cited by 78
Self-citationChapurlat, R. D., Bauer, D. C., & Cummings, S. R. (2001) · Bone · doi:10.1016/s8756-3282(01)00584-1 · Cited by 36
ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies
Chen, D., Sarikaya, N. A., Gunn, H., Martin, S. W., & Young, J. D. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.747 · Cited by 32 · cited 1×
“Assays are being developed that use OPG ligand as a capture protein as an alternative to an antihuman OPG monoclonal antibody (23).”
Method
Cited by
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Primary osteoporosis in postmenopausal women
Ji, M., & Yu, Q. (2015) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2015.02.006 · Cited by 436
“After 4e8 years, the second phase exhibits a persistent, slower loss of both trabecular and cortical bone, and is mainly attributed to reduced bone formation.(11) This is age related bone loss, which is the only phase that also happens in men.”
BackgroundEastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0726 · Cited by 407
Self-citationThe role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
“The relationship between OPG and BMD is equally mixed with negative (53), positive (58), and non-significant effects (54, 56, 57).”
BackgroundResult
Metadata
- Authors
- Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R.
- Affiliations
- University of Sheffield (GB)
- Sheffield Hallam University (GB)
- Corresponding author
- Rogers, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-10
- Volume
- 87
- Issue
- 10
- Pages
- 4470-4475
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1972546618
- Cited by
- 200
- References
- 20
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 7 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 3 · 2013: 7 · 2012: 7
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- estradiol, osteoprotegerin, bone turnover markers, bone mineral density, postmenopausal women, estrogen, bone resorption, bone formation, RANKL, osteoclasts, menopause, hip bone density, femoral neck, lumbar spine, body mass index, age, bone loss prevention, osteoporosis
- MeSH terms
- Aged, Aged, 80 and over, Analysis of Variance, Estradiol, Female, Femur, Glycoproteins, Humans, Lumbar Vertebrae, Middle Aged, Regression Analysis, Biomarkers, Bone Density, Body Mass Index, Bone Remodeling, Postmenopause, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.